SOUTH SAN FRANCISCO, CA--(Marketwire - December 01, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 6-9, 2008 at the Moscone Center in San Francisco, California. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.
